A medicine and food homologous gastric motility promoting composition, combination method, crude formulation of formula and its application

Abstract

A medicine-food homology stomach motility promoting composition, combination method, crude formulation of the formula and its application. The present invention belongs to the field of medicine-food homology food compositions. The object of the present invention is to provide a medicine-food homology stomach motility promoting composition, its combination method and application. The method of the present invention combines four monomers of medicine-food homology foods verified by experiments in a certain proportion, and based on different effective ways of their monomers, achieves the best stomach motility promoting effect, and thus successfully realizes the improvement of the stomach motility effect.

Description

Technical Field

[0001] The present invention belongs to the field of food-medicine homologous food compositions, and particularly relates to a food-medicine homologous gastric motility promoting composition, a combination method, a crude formulation of the formula, and its application. Background Art

[0002] Indigestion is a common gastrointestinal disease. Approximately 20% of the population in our country suffers from indigestion or often has related symptoms. There are many causes of indigestion, and the most common one is indigestion caused by gastric motility disorders.

[0003] Gastric motility disorders generally refer to the decline in gastric contraction function and the disorder of gastric secretion function. The environment, genetics, diet, and emotions may all lead to gastric motility disorders. Prokinetics are currently first-line drugs for the treatment of gastric motility disorders, but prokinetic drugs often have relatively large side effects and are prohibited from being sold in many regions and countries. Therefore, in clinical treatment, non-drug treatment methods such as more safely adjusting the patient's diet structure or using digestive enzyme dietary supplements are also often used, but there are few studies on the corresponding disease subtypes for these therapies. In addition, patients will only be recommended to be included in the corresponding treatment system on the premise that the symptom frequency meets the diagnostic criteria of functional gastrointestinal diseases, which ignores many people with relatively mild symptoms but still being troubled by this, especially functional abdominal distension that may be caused by gastric motility disorders. In fact, such frequent mild symptoms have a great impact on production and life.

[0004] To sum up, there is a problem that the symptoms of gastric motility insufficiency are common in the population and mostly mild, and there are also lacks of effective, clearly positioned, and side-effect-free related products in the food and medicine fields. In fact, there are many food-medicine homologous foods for promoting digestion in the food-medicine homologous catalog in our country. Some of them are included in traditional prescriptions for compatibility use, and some are not used in combination, but their monomers may have effects, with great development potential. Since there are multiple ways to cause gastric motility disorders or promote gastric motility, the mechanisms of action of different food-medicine homologous foods in promoting gastric motility may be different. It is necessary to clearly locate the mechanism of action of each food-medicine homologous food monomer, and then combine them into a formula to exert greater efficacy. Such a food formula can be eaten directly, and can also be developed into other food forms such as candies and beverages, which are more suitable for application in daily life, corresponding to the population with gastric motility insufficiency that needs to be mildly improved frequently, so it has a broad application prospect. Summary of the Invention

[0005] To solve the above technical problems, the purpose of the present invention is to provide a food-medicine homologous gastric motility promoting composition, its combination method, and application. The method of the present invention combines three food-medicine homologous food monomers verified by experiments in a certain proportion, and based on the different mechanisms of action of their monomers, achieves the best gastric motility promoting effect, and thus successfully improves the gastric motility promoting effect. The present invention provides the following technical solutions:

[0006] One of the objectives of the present invention is to provide a homologous medicine and food stomach motility promoting composition, and the homologous medicine and food stomach motility promoting composition includes hawthorn powder, chicory powder and phyllanthus emblica powder.

[0007] As a preferred embodiment of the present invention, among them: the particle sizes of the hawthorn powder, chicory powder and phyllanthus emblica powder all pass through a 120-mesh sieve.

[0008] Another objective of the present invention is to provide a combination method for a homologous medicine and food stomach motility promoting composition, and the combination method is as follows:

[0009] Any two or three of the hawthorn powder, chicory powder and phyllanthus emblica powder are stirred and mixed in proportion to obtain four rough preparations of homologous medicine and food stomach motility promoting formulations.

[0010] Another objective of the present invention is to provide a rough preparation of a homologous medicine and food stomach motility promoting formulation obtained by the above combination method, and the rough preparation includes the following components in parts by weight: 100 parts of hawthorn powder and 90 parts of chicory powder.

[0011] Another objective of the present invention is to provide a rough preparation of a homologous medicine and food stomach motility promoting formulation obtained by the above combination method, and the rough preparation includes the following components in parts by weight: 100 parts of hawthorn powder and 22.5 parts of phyllanthus emblica powder.

[0012] Another objective of the present invention is to provide a rough preparation of a homologous medicine and food stomach motility promoting formulation obtained by the above combination method, and the rough preparation includes the following components in parts by weight: 90 parts of chicory powder and 22.5 parts of phyllanthus emblica powder.

[0013] Another objective of the present invention is to provide a rough preparation of a homologous medicine and food stomach motility promoting formulation obtained by the above combination method, and the rough preparation includes the following components in parts by weight: 100 parts of hawthorn powder, 90 parts of chicory powder and 22.5 parts of phyllanthus emblica powder.

[0014] Another objective of the present invention is to provide an application of the above four rough preparations of homologous medicine and food stomach motility promoting formulations in food.

[0015] As a preferred embodiment of the present invention, among them: the food includes candies and beverages.

[0016] Compared with the prior art, the present invention has the following beneficial effects:

[0017] This application is based on different gastric motility regulation mechanisms, namely, from multiple perspectives such as the gastric internal environment, various gastrointestinal hormones, gastric pacemaker cells, and gastric mucosa. Through monomers of medicated and edible homologous substances with different onset mechanisms, multi-target regulation of gastric acid, pepsin, MTL, GAS, Ghrelin, c-kit / SCF gene, and gastric digestive gland layer can be achieved in the form of a formula, playing the role of promoting gastric motility to the greatest extent. The specific advantages are as follows:

[0018] (1) The medicated and edible homologous food formula described in the present invention can increase the daily food intake of rats.

[0019] (2) The medicated and edible homologous food formula described in the present invention can promote the gastric emptying rate of rats.

[0020] (3) The medicated and edible homologous food formula described in the present invention can regulate gastric acid secretion and promote the release of gastric protein.

[0021] (4) The medicated and edible homologous food formula described in the present invention can promote the increase in the levels of serum ghrelin and gastrin.

[0022] (5) The medicated and edible homologous food formula described in the present invention can promote the increased expression of the key gene c-kit for the proliferation and differentiation of interstitial cells.

[0023] (6) The medicated and edible homologous food formula described in the present invention can promote the repair of fundic gland cells.

[0024] (7) The food doses used in the present invention are all within the range recommended by the pharmacopoeia, without any drug toxicity, with high safety, and the dose selection of monomer medicated and edible homologous foods has been verified to be the best through preliminary dose-effect verification. In addition, since the selected materials belong to medicated and edible homologous foods, and chicory, hawthorn, phyllanthus emblica, etc. have good taste and flavor, they have great application prospects. Description of the Drawings

[0025] Figure 1 It is the graph of the average daily food intake of rats in Effect Example 1;

[0026] Figure 2 It is the graph of the gastric emptying rate of rats in Effect Example 2;

[0027] Figure 3 It is the graph of the serum gastrin content of rats in Effect Example 4;

[0028] Figure 4 It is the graph of the serum ghrelin content of rats in Effect Example 4;

[0029] Figure 5 It is the graph of the serum motilin content of rats in Effect Example 4;

[0030] Figure 6 It is the graph of the gastric antrum tissue morphology (HE staining) of rats in Effect Example 6. Detailed Embodiments

[0031] In order to make the above objects, features and advantages of the present invention more obvious and understandable, the following specifically describes the specific implementation manners of the present invention in conjunction with the embodiments of the specification.

[0032] In the following description, many specific details are set forth in order to fully understand the present invention. However, the present invention can also be implemented in other ways different from those described herein. Those skilled in the art can make similar extensions without departing from the connotation of the present invention. Therefore, the present invention is not limited by the specific embodiments disclosed below.

[0033] Secondly, the so-called "one embodiment" or "embodiment" herein refers to specific features, structures or characteristics that can be included in at least one implementation manner of the present invention. The "in one embodiment" appearing in different places in this specification does not all refer to the same embodiment, nor is it an embodiment that is separate or selectively mutually exclusive with other embodiments.

[0034] The terms "comprising", "including", "having", "containing" or any other variation thereof used in the following embodiments are intended to cover non-exclusive inclusion. For example, a composition, step, method, article or device containing the listed elements is not necessarily limited to those elements, but may include other elements not explicitly listed or elements inherent to such composition, step, method, article or device.

[0035] The experimental methods used in the following embodiments are all conventional methods unless otherwise specified. The materials, reagents, methods and instruments used, unless otherwise specified, are all conventional materials, reagents, methods and instruments in this field, and those skilled in the art can obtain them through commercial channels.

[0036] The food homologous to medicine and food involved in the following embodiments are purchased from Bozhou Yuanlongtang Pharmaceutical Co., Ltd.; the SD rats involved in the following embodiments are all purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd.; the sodium chloride, L-arginine hydrochloride, and paraformaldehyde involved in the following embodiments are purchased from China National Pharmaceutical Reagent Co., Ltd.; the enzyme-linked immunosorbent assay (ELISA) kits for rat motilin (MTL), gastrin (GAS), and ghrelin involved in the following embodiments are purchased from Shanghai Enzyme-linked Biotechnology Co., Ltd.; the Trizol lysis solution and reverse transcription kit involved in the following embodiments are purchased from Nanjing Novoprotein Biotechnology Co., Ltd.; the PCR primers involved in the following embodiments are purchased from Shanghai Bioengineering Co., Ltd.

[0037] Example 1:

[0038] The preparation method of a food homologous to medicine and food prokinetic formula crude preparation in this embodiment is carried out according to the following steps:

[0039] Step 1: Crush dried hawthorn and dried chicory, and then pass through a 120-mesh sieve to obtain hawthorn powder and chicory powder respectively;

[0040] Step 2: Take 100 g of hawthorn powder and 90 g of chicory powder, stir and mix evenly to obtain a crude preparation of hawthorn-chicory gastric motility promoting formula, and store it at 4°C.

[0041] Example 2:

[0042] The preparation method of a crude preparation of a homologous medicine and food gastric motility promoting formula in this example is carried out according to the following steps:

[0043] Step 1: Crush dried hawthorn and dried phyllanthus emblica, and then pass through a 120-mesh sieve to obtain hawthorn powder and phyllanthus emblica powder respectively;

[0044] Step 2: Take 100 g of hawthorn powder and 22.5 g of phyllanthus emblica powder, stir and mix evenly to obtain a crude preparation of hawthorn-phyllanthus emblica gastric motility promoting formula, and store it at 4°C.

[0045] Example 3:

[0046] The preparation method of a crude preparation of a homologous medicine and food gastric motility promoting formula in this example is carried out according to the following steps:

[0047] Step 1: Crush dried phyllanthus emblica and dried chicory, and then pass through a 120-mesh sieve to obtain phyllanthus emblica powder and chicory powder respectively;

[0048] Step 2: Take 22.5 g of phyllanthus emblica powder and 90 g of chicory powder, stir and mix evenly to obtain a crude preparation of chicory-phyllanthus emblica gastric motility promoting formula, and store it at 4°C.

[0049] Example 4:

[0050] The preparation method of a crude preparation of a homologous medicine and food gastric motility promoting formula in this example is carried out according to the following steps:

[0051] Step 1: Crush dried hawthorn, dried chicory and dried phyllanthus emblica, and then pass through a 120-mesh sieve to obtain hawthorn powder, chicory powder and phyllanthus emblica powder respectively;

[0052] Step 2: Take 100 g of hawthorn powder, 90 g of chicory powder and 22.5 g of phyllanthus emblica powder, stir and mix evenly to obtain a crude preparation of hawthorn-chicory-phyllanthus emblica gastric motility promoting formula, and store it at 4°C.

[0053] Effect Example 1: Influence on the daily food intake of rats with gastric motility disorder

[0054] The specific test process is as follows:

[0055] S1: Select 88 male SD rats at 7 weeks of age. After one week of adaptation, start the experiment. Randomly divide them into 11 groups, with 8 rats in each group. The 11 groups are the blank group, the model group, the domperidone group (single-drug positive reference), the Jianweixiaoshi tablets group (compound-drug positive reference), the chicory group, the hawthorn group, the phyllanthus emblica group, the Example 1 group, the Example 2 group, the Example 3 group, and the Example 4 group;

[0056] S2: The grouping and treatment are shown in Table 1 specifically.

[0057] Days 1 - 5 of the experiment are the modeling period: Except for the blank group, all groups are intraperitoneally injected with L-arginine at 5.2 g / kg on the first day and 2.6 g / kg from the second to the fifth day. The blank group is intraperitoneally injected with an equal amount of normal saline accordingly.

[0058] Days 6 - 12 of the experiment are the gavage intervention period: The solvent for all suspensions is water. The suspensions are gavaged after equilibration at room temperature for 1 h.

[0059] Among them, for the blank group and the model group: Gavage 4 mL of drinking water.

[0060] For the domperidone group: Gavage 4 mL of 1 mg / kg domperidone suspension.

[0061] For the Jianweixiaoshi tablets group: Gavage 4 mL of 1.2 g / kg Jianweixiaoshi tablets powder suspension.

[0062] For the chicory group: Gavage 4 mL of 0.93 g / kg chicory powder suspension.

[0063] For the hawthorn group: Gavage 4 mL of 1.03 g / kg hawthorn powder suspension.

[0064] For the phyllanthus emblica group: Gavage 4 mL of 0.23 g / kg phyllanthus emblica powder suspension.

[0065] For the Example 1 hawthorn + chicory group: Gavage 4 mL of 1.03 g / kg hawthorn + 0.93 g / kg chicory powder suspension.

[0066] For the Example 2 hawthorn + phyllanthus emblica group: Gavage 4 mL of 1.03 g / kg hawthorn + 0.23 g / kg phyllanthus emblica powder suspension.

[0067] For the Example 3 chicory + phyllanthus emblica group: Gavage 4 mL of 0.93 g / kg chicory + 0.23 g / kg phyllanthus emblica powder suspension.

[0068] For the Example 4 hawthorn + chicory + phyllanthus emblica group: Gavage 4 mL of 1.03 g / kg hawthorn + 0.93 g / kg chicory + 0.23 g / kg phyllanthus emblica powder suspension.

[0069] S3: During the experiment, the weight of the rats' feed was measured at a fixed time every day. On the 20th day, the rats' serum, tissues, etc. were collected for the determination of relevant indicators.

[0070] Table 1 Animal experiment design plan

[0071]

[0072]

[0073] After the experiment, the average daily food intake of the rats in each group was statistically analyzed, and the experimental results are as Figure 1 shown. It can be seen from Figure 1 that the daily food intake of the model group (20.02 g ± 1.28 g) was significantly lower than that of the blank group (23.67 g ± 0.55 g), indicating that the food intake of rats with gastric motility disorder decreased. Compared with the model group, the food intake of the other experimental groups increased to varying degrees. Among them, the food intake of the hawthorn + chicory + phyllanthus emblica group in Example 4 (23.85 ± 0.28 g) increased significantly, indicating that hawthorn + chicory + phyllanthus emblica can promote the appetite of rats and increase food intake.

[0074] Effect Example 2: Medicinal and edible homologous food monomers and their formulas can improve the gastric emptying rate of rats with gastric motility disorder

[0075] The experimental procedures such as grouping, modeling, and treatment methods of SD rats were the same as those in Effect Example 1.

[0076] After the experiment, the gastric emptying rate of half of the rats in each group was measured by the semi-solid nutritional rice paste method. The rats were intragastrically administered 3 mL / kg of semi-solid nutritional rice paste (10 g of sodium carboxymethylcellulose, 16 g of whole milk powder, 8 g of starch, 2 g of carbon powder, 200 g of distilled water) according to their body weight. After 30 minutes, the animals were sacrificed, the cardia and pylorus were ligated, the whole stomach was taken, and the total weight of the stomach was weighed. The stomach tissue was cut along the greater curvature of the stomach, and after rinsing the gastric contents, the net weight of the stomach was weighed.

[0077] Gastric emptying rate = [weight of solid paste - (total weight of stomach - net weight of stomach) / weight of solid paste] × 100

[0078] The experimental results are as Figure 2As shown, the experimental results showed that the gastric emptying rate of the rats in the blank group (74.62±2.93a) was significantly higher than that in the model group (40.05±5.52f), and the gastric emptying rate of the rats with gastric motility disorder decreased. The gastric emptying rates of the remaining experimental groups were increased to varying degrees compared with the model group. Domperidone had the greatest increase in the gastric emptying rate of the rats with gastric motility disorder (62.04±3.59b), followed by Hawthorn + Chicory + Phyllanthus emblica (61.29±5.72bc), Jianweixiaoshi tablets (60.09±3.31bcd), Hawthorn + Chicory (56.29±4.95bcde), Chicory + Phyllanthus emblica (55.91±4.95bcde), Hawthorn + Phyllanthus emblica (54.11±4.53cde), Hawthorn (53.98±4.28de), Chicory (52.98±3.38de), and Phyllanthus emblica (50.67±5.46e). Each homologous medicine and food monomer and formula group could increase the gastric emptying rate.

[0079] Whether there is a synergistic effect when the two drugs are used in combination is verified according to the King's formula q = E(A + B) / (EA + EB - EA·EB). Among them, EA and EB are the effects of single drug use, and E(A + B) is the effect of the two drugs in combination. The q value between 0.85 and 1.15 is simple addition (+), 1.15 to 1.20 is enhancement (++), greater than 1.20 is significant enhancement (+++); 0.55 to 0.85 is antagonism (-), and <0.55 is obvious antagonism (--).

[0080] In the examples of the present invention, the gastric emptying change rate and the synergistic index q value are measured as follows:

[0081] The synergistic index q1 of gastric emptying of Hawthorn + Chicory = 0.73 (-)

[0082] The synergistic index q2 of gastric emptying of Hawthorn + Phyllanthus emblica = 0.67 (-)

[0083] The synergistic index q3 of gastric emptying of Chicory + Phyllanthus emblica = 0.71 (-)

[0084] The synergistic index q4 of gastric emptying of Hawthorn + Chicory + Phyllanthus emblica = 0.94 (+)

[0085] The results showed that the synergistic effect of pairwise combination was general, and the combination of three had an additive synergistic effect.

[0086] Effect Example 3: Homologous medicine and food monomers and their formulas can regulate gastric free acid, total acid and gastric protease activity in rats with gastric motility disorder

[0087] The detection methods involved are as follows:

[0088] Determination of gastric juice free acid, total acid and protease

[0089] Half of each group of rats were anesthetized with isoflurane 4 h before sacrifice. The abdominal cavity was opened, the pyloric part was ligated, and then the abdominal cavity was sutured layer by layer and closed. When sacrificed, the entire stomach was taken after ligating the cardia, cut along the greater curvature of the stomach, the gastric contents were collected, and the clarified liquid was obtained after centrifugation at 3000 r / min for 10 min, and the gastric juice volume was recorded.

[0090] Take 0.5 mL of gastric juice and add methyl orange and phenolphthalein reagents. Titrate with 20 mmol / L NaOH solution. When the red color disappears and the orange color begins to appear, the amount of NaOH used is the end point amount of free acid. When the orange color disappears and the light red color appears, the amount of NaOH used is the end point amount of total acid.

[0091] Take 0.5 mL of gastric juice and add it to a stoppered graduated cylinder. Add 7.5 mL of 0.05 mol / L hydrochloric acid solution and shake well. Put in two self-made protein tubes, stopper the bottle mouth and incubate in a 37 °C incubator for 24 h, then take out. Measure the transparent length at both ends of the protein tube with a vernier caliper. Pepsin activity (U / mL) = average length × 2 × 16.

[0092] The experimental results are shown in Table 2-3.

[0093] Table 2 Determination of total acid, free acid, protease and gastric juice volume

[0094]

[0095]

[0096] Table 3 Determination of the excretion rates of total acid, free acid and protease

[0097]

[0098] Gastric juice is an important digestive juice in the digestive tract. High concentrations of hydrogen ions and organic acids inhibit gastric emptying. There is a parallel control mechanism between pepsin output and gastric acid, and the interaction with gastric motility has been less studied. However, there is a parallel control mechanism between pepsin output and gastric acid, and the excretion levels of gastric acid and pepsin reflect the secretory function of gastric mucosal cells. Current research generally believes that there is a connection between gastric motility and gastric secretion, but the specific mechanism is relatively complex. The excretion of gastric acid shows different performances in different research models. It is a relatively common phenomenon that excessive or insufficient gastric acid secretion and a decrease in gastric juice volume occur.

[0099] As can be seen from Table 2-3, compared with the blank group, the gastric acid secretion rate in the model group decreased, but the gastric acid concentration was high, and the gastric juice volume and pepsin activity decreased, indicating abnormal gastric acid secretion function, gastric juice secretion function, and protease excretion function in the rat gastric mucosa in this study. From the results, compared with the model group, the total acid concentration in the experimental groups of hawthorn, chicory, phyllanthus emblica, hawthorn + chicory, chicory + phyllanthus emblica, and hawthorn + chicory + phyllanthus emblica decreased significantly, and the total acid concentration in domperidone, Jianweixiaoshi tablets, and hawthorn + phyllanthus emblica decreased but not significantly; the free acid concentration in Jianweixiaoshi tablets, hawthorn, chicory, phyllanthus emblica, hawthorn + chicory, hawthorn + phyllanthus emblica, chicory + phyllanthus emblica, and hawthorn + chicory + phyllanthus emblica decreased significantly; hawthorn, hawthorn + chicory, and hawthorn + chicory + phyllanthus emblica significantly increased pepsin activity; the gastric juice volume in the domperidone group increased significantly, and there was no significant difference in the gastric juice volume in other experimental groups; the total acid excretion rate in Jianweixiaoshi tablets, chicory, phyllanthus emblica, hawthorn + chicory, chicory + phyllanthus emblica, and hawthorn + chicory + phyllanthus emblica decreased significantly; there was no significant difference in the free acid excretion rate among the groups; the protease excretion rate in domperidone, hawthorn, hawthorn + chicory, hawthorn + phyllanthus emblica, and hawthorn + chicory + phyllanthus emblica increased significantly.

[0100] In the examples of the present invention, the synergistic index q values for measuring the total gastric acid concentration, free acid concentration, and protease activity are as follows:

[0101] Synergistic index q of total acid concentration of hawthorn + chicory = 0.46 (--)

[0102] Synergistic index q of total acid concentration of hawthorn + phyllanthus emblica = 0.37 (--)

[0103] Synergistic index q of total acid concentration of chicory + phyllanthus emblica = 0.55 (--)

[0104] Synergistic index q of total acid concentration of hawthorn + chicory + phyllanthus emblica = 0.71 (-)

[0105] Synergistic index q of free acid concentration of hawthorn + chicory = 0.53 (--)

[0106] Synergistic index q of free acid concentration of hawthorn + phyllanthus emblica = 0.40 (--)

[0107] Synergistic index q of free acid concentration of chicory + phyllanthus emblica = 0.61 (-)

[0108] Synergistic index q of free acid concentration of hawthorn + chicory + phyllanthus emblica = 0.73 (-)

[0109] Synergistic index q of protease activity of hawthorn + chicory = 1.22 (+++)

[0110] Synergistic index q of protease activity of hawthorn + phyllanthus emblica = 0.89 (+)

[0111] The synergistic index q of protease activity of chicory + phyllanthus emblica is 1.13 (++).

[0112] The synergistic index q of protease activity of hawthorn + chicory + phyllanthus emblica is 1.41 (+++).

[0113] The results showed that chicory and phyllanthus emblica could better regulate gastric acid concentration, reduce the concentration of total acid and free acid, hawthorn could enhance the activity and excretion rate of pepsin, and the combined effect had a general synergistic effect on acid regulation ability and a strong synergistic effect on the increase of protease activity.

[0114] Effect Example 4: Effects of single food and its formula homologous to medicine and food on serum gastrointestinal hormones in rats with gastric motility disorder

[0115] Blood was collected by cardiac puncture, centrifuged at 3500 g for 15 min, and the supernatant was taken to obtain serum. The contents of excitatory gastrointestinal hormones in the serum were measured according to the detection methods of ghrelin, gastrin GAS and motilin MTL enzyme-linked immunosorbent assay kits respectively. The results are as Figures 3 - 5 shown.

[0116] From Figures 3 - 5It can be seen that the serum GAS content (36.16±4.95bc) and Ghrelin content (106.53±14.7b) in the blank group were significantly higher than the GAS content (24.07±3.2d) and Ghrelin content (71.02±11.09cd) in the model group. The serum MTL content (68.66±18.56ab) in the blank group was higher than that in the model group (53.52±8.69bc), but there was no significant difference, indicating that the overall secretion of excitatory gastrointestinal hormones in rats with gastric motility disorder was insufficient. Compared with the model group in terms of serum GAS content in each experimental group, the GAS content in domperidone (32.97±10.39c), Jianweixiaoshi tablets (36.71±5.73bc), Phyllanthus emblica (43.78±7.09b), Hawthorn + Chicory (40.13±7.4bc), Hawthorn + Phyllanthus emblica (46.71±11.32ab), Chicory + Phyllanthus emblica (42.39±5.17b), and Hawthorn + Chicory + Phyllanthus emblica serum (53.21±9.67a) increased significantly; compared with the model group in terms of serum Ghrelin content in each experimental group, the serum Ghrelin content in Hawthorn + Chicory (104.73±19.78b) and Hawthorn + Chicory + Phyllanthus emblica group (145.25±23.43a) increased significantly; compared with the model group in terms of serum MTL content in each experimental group, only the serum MTL in the domperidone group (89.55±15.27a) increased significantly, and there was also a tendency for the serum MTL content in Jianweixiaoshi tablets (60.88±5.39b), Hawthorn + Chicory (64.84±10.8b), Hawthorn + Phyllanthus emblica (61.51±12.06b), and Hawthorn + Chicory + Phyllanthus emblica (74.26±16.87b) to increase, but there was no significant difference.

[0117] In the embodiments of the present invention, the q value of the synergistic index for measuring the serum gastrointestinal hormone content is as follows:

[0118] The synergistic index q of serum GAS content for Hawthorn + Chicory = 6.04 (+++)

[0119] The synergistic index q of serum GAS content for Hawthorn + Phyllanthus emblica = 1.16 (++)

[0120] The synergistic index q of serum GAS content for Chicory + Phyllanthus emblica = 1.01 (+)

[0121] The synergistic index q of serum GAS content for Hawthorn + Chicory + Phyllanthus emblica = 0.90 (+)

[0122] The synergistic index q of serum Ghrelin content for Hawthorn + Chicory = 1.00 (+)

[0123] The synergistic index q of serum Ghrelin content for Hawthorn + Phyllanthus emblica = 2.80 (+++)

[0124] The synergistic index q of the serum Ghrelin content of chicory + phyllanthus emblica is 0.86 (+)

[0125] The synergistic index q of the serum Ghrelin content of hawthorn + chicory + phyllanthus emblica is 1.20 (++)

[0126] The synergistic index q of the serum MTL content of hawthorn + chicory is 0.17 (--)

[0127] The synergistic index q of the serum MTL content of hawthorn + phyllanthus emblica is 0.13 (--)

[0128] The synergistic index q of the serum MTL content of chicory + phyllanthus emblica is 0.31 (--)

[0129] The synergistic index q of the serum MTL content of hawthorn + chicory + phyllanthus emblica is 0.30 (--)

[0130] Judging from the results, hawthorn and chicory have a promoting effect on the serum Ghrelin content, phyllanthus emblica has a promoting effect on the serum GAS content, and the synergistic effect is good after combination.

[0131] Effect Example 5: Effects of the formula of medicated and edible homologous foods on the key differentiation key genes of the proliferation of gastric antral interstitial cells in rats with gastric motility disorder

[0132] After sacrificing the rats, an appropriate amount of gastric antral tissue was taken, added with Trizol lysis solution, homogenized on ice, and total RNA in the tissue was extracted; cDNA was synthesized according to the requirements of the reverse transcription kit, and after mixing with the fluorescence Mix, fluorescence quantitative PCR analysis was carried out. The primer design is shown in Table 4, and the results are shown in Table 5.

[0133] Table 4 Primer design table

[0134]

[0135]

[0136] Table 5 Expression levels of c-kit and SCF mRNA in rat gastric antral tissue

[0137]

[0138] The results showed that interstitial cells are the pacemaker cells of the gastrointestinal tract and the basis for the contraction and relaxation functions of gastric smooth muscle cells. c-kit and SCF are the key genes for the proliferation and differentiation of ICC. The expression levels of c-kit and SCF mRNA and protein in rats with gastric motility disorder decreased, and the normal functions of ICC were impaired. As shown in the table for the expression levels of c-kit and SCF in the gastric antrum tissue, compared with the blank group, the expression levels of c-kit mRNA and SCF mRNA in the model group rats decreased significantly, indicating that the number of ICC in rats with gastric motility disorder may decrease and the gastric pacing ability may decline. Compared with the model group, the expression level of c-kit mRNA in the Jianweixiaoshi tablets, Hawthorn + Chicory, and Hawthorn + Chicory + Phyllanthus emblica groups increased significantly, indicating that these food-medicinal homologous formulas have a beneficial effect on c-kit mRNA; the expression levels of SCF mRNA in Domperidone, Jianweixiaoshi tablets, Hawthorn + Chicory, Hawthorn + Phyllanthus emblica, Chicory + Phyllanthus emblica, and Hawthorn + Chicory + Phyllanthus emblica increased significantly, indicating that these food-medicinal homologous formulas have a beneficial effect on the expression of SCF mRNA.

[0139] Effect Example 6: Improvement of the gastric fundus secretory gland tissue of rats with gastric motility disorder by food-medicinal homologous food monomers and their formulas

[0140] After sacrificing the rats, collect the gastric antrum tissue of the rats and make paraffin sections of the gastric antrum of the rats. The specific experimental steps are as follows:

[0141] Take a section of the gastric pylorus at 0.5 cm from the anterior part of the duodenum and fix it with 4% paraformaldehyde for 48 h; after rinsing the fixed gastric antrum tissue with running water for 8 h, sequentially place it in 70%, 80%, and 90% ethanol solutions for dehydration, with each dehydration for 30 min, and then sequentially place it in 95% and 100% ethanol solutions, each for 20 min; place the colon sample in a 1:1 mixture of xylene and alcohol for 15 min, and then place it in xylene I and xylene II for 15 min each; transfer the colon tissue to a mixture of xylene and paraffin (each half) for 15 min, and then place it in paraffin I and paraffin II for infiltration for 1 h each, with the temperature maintained at 60 °C; use a Leica paraffin embedding machine to embed the gastric antrum tissue in a re-melted wax block, and use a tissue slicer to section the embedded tissue, with a thickness of 5 μm; after sticking the slices, air-dry them and place them in an oven at 62 °C for 1 h.

[0142] The results are as Figure 6As shown, the results show that in normal rats (blank group), the gastric fundic gland layer accounts for about half of the mucosal thickness. In the model group, the gastric antrum tissue structure is complete and no obvious damage is seen, meeting the requirement that there is no organic damage in gastric motility disorder. However, the glands in the mucosal layer of the gastric antrum only account for about one-fifth of the total mucosal thickness, indicating that the function of the gastric fundic mucosa layer in rats with gastric motility disorder is affected. Compared with the number of gastric fundic glands in the model group, the proportion of the gastric fundic gland layer in the domperidone, Jianweixiaoshi tablets, chicory, hawthorn + chicory, chicory + Phyllanthus emblica, and hawthorn + chicory + Phyllanthus emblica groups increases. The chicory and the formula groups containing chicory have better effects, and the proportion of the gastric fundic gland layer in the corresponding formulas is higher, indicating that chicory has a certain effect on repairing the gastric fundic gland layer, and the combined effect is better.

[0143] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not restrictive. Although the present invention has been described in detail with reference to the preferred embodiments, those of ordinary skill in the art should understand that the technical solutions of the present invention can be modified or equivalently replaced without departing from the spirit and scope of the technical solutions of the present invention, and they should all be covered by the scope of the claims of the present invention.

Claims

1. A medicine-food homologous gastric motility promoting composition, characterized in that, It is composed of 100 parts of hawthorn powder, 90 parts of chicory powder and 22.5 parts of phyllanthus emblica powder.

2. The composition according to claim 1, wherein The particle sizes of the hawthorn powder, chicory powder and phyllanthus emblica powder all pass through a 120-mesh sieve.

3. A method for preparing the composition according to claim 1 or 2, characterized in that, The method is as follows: Stir and mix the hawthorn powder, chicory powder and phyllanthus emblica powder in proportion to obtain a crude preparation of the medicine-food homologous gastric motility promoting formula.

4. Application of the crude preparation of the medicine-food homologous gastric motility promoting formula prepared by the method described in claim 3 in the preparation of food.

5. The application according to claim 4, characterized in that, The food includes candies and beverages.

Images